Ibio, INC

iBio, Inc. announced positive preclinical data from an NHP study showing its Activin E antibody candidate, IBIO-610, may preserve muscle mass when combined with semaglutide.

iBio, Inc. presented an updated corporate overview, detailing its next-generation antibody programs targeting obesity and cardiometabolic diseases, alongside a robust cash runway.

iBio, Inc. announced its fiscal year 2026 financial results, detailing progress in its obesity and cardiometabolic pipeline, including advancements in its IBIO-600 and IBIO-610 programs, alongside successful capital raises.

iBio, Inc. announced the appointment of Dr. Molly Carr as its new Chief Medical Officer, a move aimed at bolstering its clinical strategy and advancing its pipeline.

iBio, Inc. announced its 2026 Annual Meeting of Stockholders will be held on October 14, 2026, and has updated deadlines for shareholder proposals and director nominations.

iBio, Inc. announced new preclinical data for its Activin E antibody candidate, IBIO-610, showing significant reduction in active Activin E levels and potential for fat-selective weight loss.

iBio, Inc. reports significant R&D investment and progress in its preclinical pipeline, particularly for obesity and cardiometabolic diseases, while managing cash reserves and exploring strategic partnerships.

iBio, Inc. reported an increased net loss for Q1 FY2026 but significantly bolstered its cash position with $46.5 million net proceeds from an August 2025 public offering, fueling its AI-driven cardiometabolic and obesity antibody pipeline.

iBio, Inc. reports a net loss of $5.7 million for Q1 FY2026, driven by increased R&D, but strengthens its liquidity with a $46.5 million net capital raise to advance its AI-driven obesity and cardiometabolic pipeline.

iBio Inc. offers warrant holders an inducement to exercise existing warrants at a reduced price, while also reporting its financial results for the third quarter of fiscal year 2025, highlighting its focus on AI-driven antibody discovery.

iBio's Q2 2025 results highlight the company's strategic shift towards AI-driven antibody discovery, while acknowledging substantial doubt about its ability to continue as a going concern.

iBio's Q1 2025 report highlights a shift towards AI-driven antibody development, with reduced operating expenses and a focus on strategic collaborations.

iBio, Inc. reports progress in its AI-driven antibody development for obesity and cardiometabolic diseases, with its IBIO-600 entering Phase 1 trials and securing substantial funding.

iBio, a preclinical biotechnology company, is leveraging AI to develop precision antibodies for cardiometabolic and obesity diseases, advancing key candidates and securing significant capital.

iBio, Inc. has filed an amendment to its annual report to correct a typographical error in the signature date of the independent auditor's report.

iBio, Inc. transitioned to an AI-powered biotech company focused on precision antibody development, divesting its CDMO facility and forming strategic collaborations.

Elizabeth Stoner, a Director of iBio, Inc., received 38,000 shares of common stock on October 14, 2026.

Alexandra Kropotova, a Director of iBio, Inc., received 38,000 shares of common stock on October 14, 2026.

David Arkowitz, a Director of iBio, Inc., received 38,000 shares of common stock on October 14, 2026.

William D Clark, a Director of iBio, Inc., received 38,000 shares of common stock on October 14, 2026.

Antonio Bernardino Guimaraes Parada, a Director of iBio, Inc., received 38,000 shares of common stock on October 14, 2026.

Gary Sender, a Director of iBio, Inc., received 38,000 shares of common stock on October 14, 2026.

iBio, Inc. has scheduled its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, and executive compensation, while disclosing continued negative net income and a significant decline in Total Shareholder Return.

iBio, Inc. has scheduled its 2024 Annual Meeting of Stockholders for November 21, 2024, to vote on the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 5,068,882 shares of iBio, Inc. common stock, representing 9.99% of the outstanding shares.

Logos Global Management and associated entities have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in iBio, Inc.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in iBio, Inc. as of March 31, 2026.

EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 4.6% beneficial ownership stake in iBio, Inc.

Cormorant Asset Management, LP and Bihua Chen have reported an increased beneficial ownership of iBio, Inc. common stock, reaching 9.99% through the exercise of warrants.

Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 9.9% of iBio, Inc. common stock, primarily through warrants, subject to a 9.99% ownership blocker.